Recently, Xinlitai announced that its independently developed innovative drug SAL0145 Injection (project code: SALO0145) for the treatment of metabolic dysfunction associated steatohepatitis (MASH) has been accepted for clinical trial application.
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablets
(3)Capsules
(4)Spray
(5)Pill press machine
https://www.achievechem.com/pill-press
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-4-009
Tirzepatide CAS 2023788-19-2
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
We provide tirzepatide powder, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/news/peptides-price-list-of-bloom-tech-85355837.html
SALO145 is a small interfering nucleic acid drug (siRNA), and preclinical studies have shown that SAL0145 has the potential to treat MASH. If successfully developed and approved for market, it is expected to provide patients with new medication options, meet unmet clinical needs, and further enrich the company's innovative product pipeline in the chronic disease field. Small interfering RNA (siRNA) is usually a short double stranded RNA composed of base pairs, which achieves specific silencing of pathogenic target genes mRNA at the transcriptional level through RNAI mechanism, achieving the goal of precise treatment of diseases.
SiRNA drugs can accurately target pathogenic genes and have the advantages of not easily developing drug resistance and long-lasting efficacy. The frequency of administration is reduced, greatly improving patient compliance. It is expected to break the traditional drug treatment regimen and has great potential for application in the field of chronic disease treatment.
The first Smeaglutide nasal spray in the world was approved in China
On January 12, 2026, CDE official website showed that Smeaglutide nasal spray declared by World Link Pharmaceutical was approved for clinical use, which was suitable for long-term weight management of adult patients on the basis of diet control and increased physical activity.
The initial body mass index (BM) met the following conditions: ≥ 28kg/m2 (obesity), or ≥ 24kg/m2 to<28kg/m2 (overweight), and there was at least one droop related complication, such as hyperglycemia, hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. The registration classification was 2.2.Siluridine from Shiling Pharmaceutical is a nasal spray agent developed based on a mucosal delivery platform, which has the advantages of avoiding first pass effects and improving bioavailability;
Non invasive drug administration, high compliance, more conducive to disease treatment and management; Convenient medication and self administration.
On January 7, 2026, World Link Pharmaceutical announced that Smeaglutide nasal spray was approved clinically by the US FDA, which is expected to become the third mainstream dosage form after injection and oral preparations.
In addition to mucosal delivery platform, Shiling Pharmaceutical has also developed a transdermal delivery platform. In December 2024, the first domestically developed and fully intellectual property innovative transdermal patch based on this platform was approved for clinical use for the first time. It is used as monotherapy for patients with primary Parkinson's disease and in combination therapy with levodopa for patients with end dose fluctuations
Saint Yin Biotechnology SGB-7342 (INHBE siRNA) completed the first subject administration
On January 13, 2026, Shengyin Biotechnology, a clinical stage biotechnology company focused on innovative RNA interference (RNA) therapy development, announced that its independently developed small interfering RNA (siRNA) candidate drug SGB7342 had completed the first subject administration in the first phase clinical trial of treating obesity in China at the First Hospital of Jilin University. This randomized, double-blind, placebo-controlled, single dose escalation Phase 1 clinical study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacological characteristics of SGB 7342 in overweight and obese patients.
SGB-7342 is an siRNA candidate drug targeting the Inhibin BE subunit (INHBE) for the treatment of obesity, developed using proprietary GaINAC coupling delivery technology and chemical modification technology from Saint Yin Biotechnology. The platform technology has demonstrated potential best in class features in phase 1 clinical trials of multiple siRNA drugs under development by the company.
SGB-7342 specifically silences the expression of INHBE gene through RNA technology, thereby reducing the level of its encoded protein ActinVvin E and effectively inhibiting downstream signaling pathway activity related to lipid metabolism and energy consumption. Preclinical studies have shown that SGB-7342 can effectively and persistently silence INHBE expression, significantly reduce body weight and fat mass, while maintaining muscle mass, and demonstrate good safety and tolerability.
